ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis: EU Backs Afinitor in Breast Cancer

ZURICH--The European Medicines Agency Friday recommended Novartis AG's (NVS) cancer drug Afinitor for approval in the European Union for the treatment of advanced breast cancer, supporting the Swiss company's hopes that the drug may become a blockbuster as it wins approval for use in different types of cancer. Novartis said the EMA's Committee for Medicinal Products for Human Use is backing the use of Afinitor tablets, in combination with hormone therapy, to treat advanced forms of breast cancer in certain women. The Basel-based company said it is submitting the drug for approval worldwide for a certain type of advanced breast cancer. If granted, this will be the fifth indication for Afinitor, which is already approved to treat kidney cancer, as well as certain kinds of brain and pancreatic tumors. Such extensions of the drug's therapeutic indications are likely to pave the way for Afinitor to become a best-seller thanks to its potential in various types of cancer. In April, the U.S. Food & Drug Administration granted wider approval to Afinitor, whose generic name is everolimus, to treat non-cancerous kidney tumors that don't require immediate surgery, after the drug was approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs failed. Afinitor, a pill taken once daily, blocks the uncontrolled activity of a protein called mTOR, which plays a role in the development and growth of certain tumors. EMA's nod is based on data from a late-stage trial involving 724 patients with HR+/HER2- advanced breast cancer, which affects an estimated 220,000 women globally each year. The study found that Afinitor combined with hormonal therapy increased the time it took cancer to progress to over seven months, compared with about three months using hormonal therapy alone. Novartis said the European Commission generally follows CHMP's recommendations and is expected to make a decision within three months. Write to Marta Falconi at marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
07/29/201508:10:07GSK Posts Sharp Fall in Profit
07/29/201507:29:46Novartis Spins Off Three Pipeline Drugs Into New Company
07/22/201519:45:14ADRs End Lower; National Bank of Greece, Petrobras Trade Actively
07/21/201518:40:12ADRs End Mixed; Infosys Rises
07/21/201515:19:03Novartis Can Sell Copycat of Amgen's Neupogen in September, Court...
07/21/201502:42:34Novartis Pressured by Dollar Strength -- Update
07/21/201502:40:10Novartis Pressured by Dollar Strength
07/21/201502:27:09Novartis Pressured by Dollar Strength
07/21/201501:53:33Novartis Pressured by Dollar Strength
07/17/201509:00:55Novartis AG 2Q 2015 -- Forecast
07/14/201507:13:03Midyear Report Card: Grading My Biotech Predictions for 2015
07/12/201511:02:03$1.5 Trillion Reasons to Invest in These Companies
07/09/201516:04:03This Week's Top Healthcare News Could Cause These Stocks Pop...
07/07/201519:52:49Novartis's Heart Failure Drug Is Approved by FDA - Update
07/07/201519:29:13Novartis's Heart Failure Drug Is Approved by FDA - Update
07/07/201518:00:18Novartis Heart Failure Drug Approved by FDA
07/07/201517:57:19Novartis Heart Failure Drug Approved by FDA
07/02/201503:48:47Ergomed Appoints Andrew Mackie as Chief Business Officer
06/29/201517:51:48ADRs End Lower; National Bank of Greece Drops Sharply
06/29/201503:39:07Novartis Buys Drug Development Company Spinifex Pharmaceuticals

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad